Isolation and characterization of a novel immunomodulating fraction from soybeans.
A novel immunomodulating fraction, SP-MAF1, was isolated from soybeans as a polysaccharide-protein complex by hot water extraction followed by acid treatment, ethanol treatment, and chromatography on a DEAE-Sepharose CL-6B column, and was characterized in some biological activities. SP-MAF1 increased glycolysis and IL-1 production by macrophages, but did not affect TNF production. SP-MAF1 also increased splenocyte proliferation that was induced by LPS and ConA, and ConA-induced production of IL-2 by splenocytes. In an in vivo test, the mean survival times of SP-MAF1-treated mice bearing FM3A were significantly longer than those of non-treated group. Since SP-MAF1 affected macrophages and splenocytes but not tumor cell growth, this effect may be mediated by the host immune system. Furthermore SP-MAF1 had a capacity to suppress the TNBS-induced DTH reaction. These results suggested that SP-MAF1 could either enhance or suppress immune functions.
Koga
T
T
Research and Development Division, Kikkoman Corporation, Chiba, Japan.
Kikuchi
M
M
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006019:Glycolysis / Q000187:drug effects; D007375:Interleukin-1 / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D008809:Mice, Inbred C3H; D010940:Plant Proteins / Q000302:isolation & purification* / Q000494:pharmacology; D011134:Polysaccharides / Q000302:isolation & purification* / Q000494:pharmacology; D013025:Glycine max / Q000737:chemistry*; D013154:Spleen / Q000166:cytology / Q000187:drug effects; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000276:Adjuvants, Immunologic; D007375:Interleukin-1; D010940:Plant Proteins; D011134:Polysaccharides; D014409:Tumor Necrosis Factor-alpha